Buy or sell Jounce Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

2017 IPO

Jounce Therapeutics Stock

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

About Jounce Therapeutics Stock

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Funding History

February 2013$47.0M
April 2015$56.0M

Management

Director of Business Development and Operations

Jason Fuller

Founder

Padmanee Sharma

CBO

Jigar Raythatha

Interim CEO

Cary Pfeffer

Founder

Thomas F. Gajewski

Founder

Drew Pardoll

CTO

Robert I. Tepper

Interim Chief Technology Officer

Robert Kamen

CEO

Rich Murray

Vice President of Research

Michael Briskin

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Jounce Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 130K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo